Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | serine/threonine protein kinase | 0.0232 | 0.0187 | 0.3898 |
Brugia malayi | Protein kinase domain containing protein | 0.0284 | 0.0325 | 0.6772 |
Loa Loa (eye worm) | hypothetical protein | 0.0284 | 0.0325 | 0.6772 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.3952 | 1 | 1 |
Loa Loa (eye worm) | CAMK/CAMKL/CHK1 protein kinase | 0.0168 | 0.0021 | 0.0436 |
Echinococcus granulosus | c-Jun N-terminal kinases | 0.0232 | 0.0187 | 0.5755 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0343 | 0.0481 | 1 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.3952 | 1 | 0.5 |
Echinococcus multilocularis | c Jun NH2 terminal kinase | 0.0232 | 0.0187 | 0.5755 |
Loa Loa (eye worm) | hypothetical protein | 0.0343 | 0.0481 | 1 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.3952 | 1 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0343 | 0.0481 | 1 |
Onchocerca volvulus | 0.0277 | 0.0308 | 0.6417 | |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.3952 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0284 | 0.0325 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0343 | 0.0481 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/JNK protein kinase | 0.0232 | 0.0187 | 0.3898 |
Brugia malayi | Kringle domain containing protein | 0.0284 | 0.0325 | 0.6772 |
Schistosoma mansoni | hypothetical protein | 0.0284 | 0.0325 | 0.6772 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0284 | 0.0325 | 0.6772 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0513 | 0.093 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0168 | 0.0021 | 0.0436 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0513 | 0.093 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0513 | 0.093 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.3952 | 1 | 1 |
Onchocerca volvulus | 0.0343 | 0.0481 | 1 | |
Toxoplasma gondii | kringle domain-containing protein | 0.0284 | 0.0325 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0168 | 0.0021 | 0.0436 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0284 | 0.0325 | 1 |
Brugia malayi | Trypsin family protein | 0.0343 | 0.0481 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0513 | 0.093 | 0.5 |
Onchocerca volvulus | 0.0284 | 0.0325 | 0.6772 | |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.3952 | 1 | 0.5 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0284 | 0.0325 | 1 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.3952 | 1 | 0.5 |
Brugia malayi | Stress-activated protein kinase jnk-1 | 0.0232 | 0.0187 | 0.3898 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0284 | 0.0325 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0513 | 0.093 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 125.8925 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.